Get the Stockscreener App
41.25
3.17%
-1.35
Veracyte Inc stock is traded at $41.25, with a volume of 1.67M.
It is down -3.17% in the last 24 hours and down -27.15% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
See More
Previous Close:
$42.60
Open:
$42.54
24h Volume:
1.67M
Relative Volume:
1.29
Market Cap:
$3.32B
Revenue:
$541.74M
Net Income/Loss:
$88.01M
P/E Ratio:
37.98
EPS:
1.0862
Net Cash Flow:
$155.34M
1W Performance:
-12.64%
1M Performance:
-27.15%
6M Performance:
+15.32%
1Y Performance:
+37.32%
1-Day Range:
$41.00
$43.12
1-Week Range:
$41.00
$47.75
52-Week Range:
$28.25
$60.91
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, NTRA, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
41.25 | 3.59B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
588.29 | 222.96B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.45 | 144.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
309.93 | 45.54B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
550.96 | 44.95B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
148.53 | 41.87B | 7.23B | 1.41B | 1.09B | 4.979 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte Inc (VCYT) Shares Fall 3.2% -- GF Value Says Still Over - GuruFocus
Veracyte Debuts Prosigna Breast Test in the U.S. - Medical Product Outsourcing
Zacks Research Upgrades Veracyte (NASDAQ:VCYT) to Strong-Buy - MarketBeat
Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT - MarketBeat
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
A Look at Veracyte Inc (VCYT) After 3.7% Decline -- GF Value $38 - GuruFocus
Amundi Sells 116,588 Shares of Veracyte, Inc. $VCYT - MarketBeat
How Investors May Respond To Veracyte (VCYT) Raising 2026 Revenue Guidance After Returning To Profit - Sahm
Veracyte at canaccord growth conference: growth balanced with margins By Investing.com - Investing.com Canada
Veracyte at canaccord growth conference: growth balanced with margins - Investing.com
Veracyte (VCYT) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Veracyte: Diagnostics With Favorable Economics (NASDAQ:VCYT) - Seeking Alpha
Veracyte Inc (VCYT) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Veracyte: Core Growth Funds Prosigna And TrueMRD (NASDAQ:VCYT) - Seeking Alpha
Royal Bank of Canada Grows Stock Holdings in Veracyte, Inc. $VCYT - MarketBeat
Veracyte, Inc. $VCYT Shares Sold by Janus Henderson Group PLC - MarketBeat
CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Cuts Target Price to $50 - Moomoo
Empowered Funds LLC Buys 68,171 Shares of Veracyte, Inc. $VCYT - MarketBeat
Results: Veracyte, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Veracyte (NASDAQ:VCYT) Shows Affordable Growth Potential - ChartMill
Renaissance Technologies LLC Takes Position in Veracyte, Inc. $VCYT - MarketBeat
VERACYTE INC : PIPER SANDLER CUTS TARGET PRICE TO $54.00 FROM $66.00 - Bitget
Medicare Coverage Granted for Veracyte’s Test for Muscle-Invasive Bladder Cancer - Medical Product Outsourcing
Guggenheim Reaffirms Their Buy Rating on Veracyte (VCYT) - The Globe and Mail
Stephens Issues Pessimistic Forecast for Veracyte (NASDAQ:VCYT) Stock Price - MarketBeat
Veracyte (NASDAQ:VCYT) Price Target Cut to $44.00 by Analysts at Morgan Stanley - MarketBeat
Veracyte, Inc. (VCYT): Investor Outlook Reveals a 31.35% Potential Upside Amid Strong Analyst Ratings - directorstalkinterviews.com
Arrowstreet Capital Limited Partnership Takes Position in Veracyte, Inc. $VCYT - marketbeat.com
Veracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests - Sahm
Canaccord cuts Veracyte stock price target to $50 on revenue outlook - Investing.com South Africa
VERACYTE INC : CANACCORD GENUITY CUTS TARGET PRICE TO $50 FROM $60 - Bitget
VERACYTE, INC. 2026: Revenue $150.32M, EPS $0.31— 10-Q Summary - TradingView
Veracyte | 10-Q: Q2 2026 Earnings Report - Moomoo
Piper Sandler Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $66 - moomoo.com
Needham raises Veracyte stock price target to $69 on strong Q2 beat - Investing.com Nigeria
Veracyte (NASDAQ:VCYT) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Transcript : Veracyte, Inc., Q2 2026 Earnings Call, Jul 30, 2026 - marketscreener.com
Is Veracyte Inc (VCYT) Still a Strong Investment After Q2 Earnin - GuruFocus
Earnings call transcript: Veracyte beats Q2 2026 estimates but shares fall after hours - Investing.com
Veracyte Q2 Non-GAAP Earnings, Revenue Rise; 2026 Revenue Guidance Raised - Moomoo
Veracyte, Inc. Raises Earnings Guidance for the Year 2026 - marketscreener.com
(VCYT) Veracyte Now Expects Full Year 2026 Revenue Range $590 Million$596 Million, vs. FactSet Est of $586.4 Million - marketscreener.com
Veracyte to offer live audio webcasts for two investor chats - Stock Titan
VCYT|Veracyte Inc|Price:55.615|Chg%:-0.995 - TradingKey
Veracyte Inc (VCYT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
VCYT|Veracyte Inc|Price:56.610|Chg%:-1.270 - TradingKey
TradingKey - TradingKey
VCYT|Veracyte Inc|Price:47.220|Chg%:+1.070 - TradingKey
Veracyte Inc (VCYT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Veracyte Inc (NASDAQ:VCYT) Shows a High Growth Momentum Breakout Setup Near Resistance - ChartMill
ETFs Investing in Veracyte, Inc. Stocks - TradingView
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):